Supply chain woes, input costs push Medtech companies to start making in India

The weakening of the rupee versus the dollar, freight charges that rose by five times from pre-pandemic levels and high import duties have increased the cost of imports for these companies in India, pushing them to evaluate possibilities of shifting a part of manufacturing to the country, industry executives told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6SWZkG5
via IFTTT